Abstract | AIM: METHODS: The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon cancer in patients who underwent SABR; patients receiving previous chemotherapy alone or in combination with bevacizumab; Karnofsky performance status >80; life expectancy >6 months; at least 6 months' follow-up after SABR; presence of KRAS mutation. The results were compared with those of a similar cohort of patients with irradiated lung lesions from colorectal cancer in whom bevacizumab was not previously administered. RESULTS: A total of 40 lung metastases were analyzed. The complete response rate after SABR was higher in patients who had received bevacizumab than in those who had not (p = 0.04). Additionally, in the bevacizumab group, a higher rate of post-SABR complete response was observed in case of oligopersistent versus oligorecurrent metastases (p = 0.001). CONCLUSIONS: In the setting of lung oligometastases from colon cancer the present study attested the higher efficacy of SABR after bevacizumab administration. Further studies in this field of research are strongly advocated.
|
Authors | Rosario Mazzola, Umberto Tebano, Dario Aiello, Gioacchino Di Paola, Niccolò Giaj-Levra, Francesco Ricchetti, Sergio Fersino, Alba Fiorentino, Ruggero Ruggieri, Filippo Alongi |
Journal | Tumori
(Tumori)
Vol. 104
Issue 6
Pg. 423-428
(Dec 2018)
ISSN: 2038-2529 [Electronic] United States |
PMID | 29737958
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Bevacizumab
(therapeutic use)
- Colonic Neoplasms
(pathology)
- Combined Modality Therapy
- Humans
- Lung Neoplasms
(radiotherapy, secondary)
- Middle Aged
- Radiosurgery
(adverse effects, methods)
- Retrospective Studies
|